A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of -cresol sulfate, -cresol glucuronide, indoxyl sulfate, and indoxyl glucuronide in HepaRG culture medium and the demonstration of mefenamic acid as a potent and selective detoxifying agent.

Background: -cresol and indole are uremic compounds which undergo sulfonation to generate the highly toxic -cresol sulfate (CS) and indoxyl sulfate (IxS). They are also subjected to glucuronidation to produce the less toxic -cresol glucuronide (CG) and indoxyl glucuronide (IG). We developed and validated an assay to quantify these metabolites in HepaRG cells. We also tested the effects of mefenamic acid on their in-situ formations in relation to the development of cellular necrosis.

Research Design And Methods: HepaRG cells were exposed to -cresol or indole (0-1 mM) with mefenamic acid (0-3000 nM) for 24 hours to generate uremic metabolites. Cells were also exposed to 0.5 mM -cresol or indole with/without 30 nM mefenamic acid to characterize lactate dehydrogenase (LDH) release.

Results: The assay exhibited high sensitivity and wide calibration ranges covering human concentrations. HepaRG cells also generated physiologically-relevant concentrations of each metabolite. Mefenamic acid inhibited CS formation in a concentration-dependent manner without affecting CG, IxS, or IG. Mefenamic acid also reduced LDH release from -cresol (by 50.12±5.86%) or indole (56.26±3.58%).

Conclusions: This novel assay is capable of quantifying these metabolites in HepaRG cells. Our novel findings suggest that mefenamic acid can be potentially utilized therapeutically to attenuate CS-associated toxicities.